Syncom Formulations Q1 FY27 Results: Revenue Rs 125 Cr, PAT Rs 24 Cr and Key Highlights

Syncom Formulations Q1 FY27 results were announced on August 11, 2026, reporting a net profit (PAT) of Rs 24 crore, up 57.71% from Rs 15 crore in Q1 FY26. Revenue from operations grew 7.38% year on year to Rs 125 crore from Rs 116 crore in Q1 FY26. The Syncom Formulations Q1 FY27 results are on a consolidated basis for the quarter ended June 30, 2026.

Click Here – Get Free Investment Predictions

Syncom Formulations Q1 FY27 Financial Highlights

The table below summarises the key financial metrics from the Syncom Formulations Q1 FY27 results compared with the same quarter of the previous year (Q1 FY26).

Metric	Q1 FY27 (Jun 2026)	Q1 FY26 (Jun 2025)	YoY Change
Revenue from Operations (Rs Cr)	Rs 125 Cr	Rs 116 Cr	+7.38%
Gross Profit (Rs Cr)	Rs 24 Cr	Rs 14 Cr	+70.51%
Net Profit / (Loss) – PAT (Rs Cr)	Rs 24 Cr	Rs 15 Cr	+57.71%

Syncom Formulations Q1 FY27 Performance Analysis

Use the Univest Screener to Track Live Fundamentals of Indian Stocks

Syncom formulations q1 fy27 results show revenue growth of 7.38% year on year to Rs 125 crore. Gross profit improved to Rs 24 crore from Rs 14 crore in Q1 FY26.

Net profit in the June 2026 quarter stood at Rs 24 crore, a 57.71% increase year on year. Investors tracking Syncom Formulations quarterly results should verify these figures against the official BSE and NSE filings.

Key Business Factors in Syncom Formulations Q1 FY27

1. Revenue Growth Expanded the Top Line

Revenue grew 7.38% yoy to rs 125 crore from rs 116 crore a year earlier. Demand conditions in the Pharmaceuticals segment supported the volume and realisation improvement seen in the June 2026 quarter.

2. Gross Profit Reflected Operational Gains

Gross profit improved to Rs 24 crore from Rs 14 crore in Q1 FY26, a 70.51% movement year on year. Better pricing and cost control contributed to the gain.

3. Net Profit Growth Signals Improving Profitability

PAT rose to Rs 24 crore, up 57.71% from Rs 15 crore in Q1 FY26. The profitability improvement reflects the company's ability to convert revenue growth into bottom-line gains within the Pharmaceuticals space.

Dividend Details

No dividend has been declared alongside the Syncom Formulations quarterly results for the quarter ended June 2026. Investors may track future announcements via BSE India and NSE India portals.

Syncom Formulations FY27 Outlook After Q1 Results

Syncom Formulations Q1 FY27 results set a broadly positive tone for the full financial year. Revenue grew 7.38% yoy to rs 125 crore from rs 116 crore a year earlier and a net profit (PAT) of Rs 24 crore provide a foundation for further improvement. Investors monitoring Syncom Formulations Q1 results should track demand conditions in Pharmaceuticals, input cost trajectories, and any capacity or business expansion announcements that could shape earnings through the remainder of FY27.

Syncom Formulations Stock Performance

Download the Univest iOS App or Univest Android App to track Syncom Formulations live share price and upcoming quarterly results.

Syncom Formulations share price stood at Rs 14.60 on August 11, 2026, the day the quarterly results were declared. Post-results, the market will assess whether the Pharmaceuticals company's financial performance justifies the current valuation. Investors should verify the latest price and fundamentals on BSE and NSE before making any investment decision.

Key Risks to Watch After Syncom Formulations Q1 FY27 Results

1. Sector-Specific Demand Headwinds

A slowdown in the Pharmaceuticals sector could weigh on Syncom Formulations revenue and profitability beyond what the June 2026 quarter already reflects.

2. Input Cost and Margin Pressure

Rising raw material or operational costs could compress gross margins and limit net profit recovery in subsequent quarters of FY27.

3. Macroeconomic and Regulatory Uncertainty

Inflation, interest rate movements, and regulatory changes remain key risks to the earnings trajectory of Syncom Formulations through FY27.

Conclusion

Syncom Formulations Q1 FY27 results report revenue of Rs 125 crore and a net profit (PAT) of Rs 24 crore, up 57.71% from Rs 15 crore in Q1 FY26. The June 2026 quarterly performance reflects the company's position in the Pharmaceuticals space. Investors should study the full financials on BSE and NSE and consult a SEBI-registered advisor before making any investment decision.

Frequently Asked Questions on Syncom Formulations Q1 FY27 Results

When were the Syncom Formulations Q1 FY27 results announced?

Ans. The June 2026 quarterly results for Syncom Formulations were announced on August 11, 2026, covering the quarter ended June 30, 2026. The consolidated results were filed with BSE and NSE on the same date.

What is the PAT in the Syncom Formulations Q1 FY27 results?

Ans. PAT (net profit) stood at Rs 24 crore in the June 2026 quarter, up 57.71% from Rs 15 crore in Q1 FY26.

What was the revenue in the Syncom Formulations Q1 FY27 results?

Ans. Revenue for the June 2026 quarter rose 7.38% year on year to Rs 125 crore from Rs 116 crore in Q1 FY26.

Did Syncom Formulations announce any dividend with the Q1 FY27 results?

Ans. No dividend has been declared alongside the June 2026 quarterly results. Investors may track future Syncom Formulations dividend announcements through the BSE and NSE portals.

What is the Syncom Formulations FY27 outlook after Q1 results?

Ans. The June 2026 quarterly performance signals a positive start to FY27 for Syncom Formulations. Key factors to watch include revenue trends, margin performance, and Pharmaceuticals sector demand through the rest of the financial year.

Is Syncom Formulations a good buy after Q1 FY27 results?

Ans. The Q1 FY27 financial performance of Syncom Formulations reflects improving trends in the June 2026 quarter. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor.